By way of clarity, we wish to emphasize that our Commentary was focused on the emerging clinical and pharmacological evidence that rescue combination inhalers are more effective than currently recommended short-acting β2-agonists for all degrees of asthma severity. At the end of our Commentary we speculated that in the future it might be even possible to show that the use of a rescue combination inhaler alone is sufficient to control asthma. Although we agree with some of the concerns raised by Drs Bogaerts and de Pauw, still we believe that the option of using the combination as rescue alone without regular maintenance therapy at least needs to be tested in controlled trials. In an era in which we desire to personalize medicine, some patients with asthma might accept a certain degree of symptoms,2 while adjusting the amount of treatment in response to symptoms, and forgo the total symptom control that is currently attainable (even with the most stringent step-up approach) only in around 40% of patients.3 Patients with more severe asthma would take more inhaled steroid along with bronchodilators, whereas taking a β2-agonist alone would not improve their control. In the real world, the same group of patients is likely to take little maintenance inhaled corticosteroid and thus will not be well controlled.